ArticleJournal of neurology2020
Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications.
Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Prevalence of hallucinations in Parkinson's patients: meta-analysis of International studies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Pooled it
- Brain-first and body-first subtypes of Lewy body disease.Nature reviews. Neurology · 2026Review
- Disease modification in advanced Parkinson's disease: a review and roadmap for paving the way for next-generation interventions.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Revealing Non-Motor Symptom Profiles of Orthostatic Hypotension Subtypes in Parkinson's Disease: Insights From a Multidimensional Case-Control Study.Clinical and translational science · 2026Article
- Pharmacogenetics in advanced Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Inter-relationship of the age of onset to the concept of brain-first versus body-first Parkinson's disease.Journal of Parkinson's disease · 2025Article
- The natural history of body-first versus brain-first Parkinson's disease subtypes.Journal of neurology · 2025Article
- Quantification of rehabilitation for patients with Parkinson's disease and related disorders using wearable devices; a proof of concept.Frontiers in neurology · 2025Article
- Disease progression subtypes of Parkinson's disease based on milestone events.Journal of neurology · 2024Article
- On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.CNS drugs · 2024Article
- Evaluating the Diagnostic Potential of Combined Salivary and Skin Biomarkers in Parkinson's Disease.International journal of molecular sciences · 2024Article
- Parkinson's Disease and Dementia with Lewy Bodies: One and the Same.Journal of Parkinson's disease · 2024Review
- The Body, the Brain, the Environment, and Parkinson's Disease.Journal of Parkinson's disease · 2024Review
- Advice to People with Parkinson's in My Clinic: Orthostatic Hypotension.Journal of Parkinson's disease · 2024Article
- Investigating the potential effects of α-synuclein aggregation on susceptibility to chronic stress in a mouse Parkinson's disease model.Pharmacological reports : PR · 2023Article
- 15-Year Subthalamic Deep Brain Stimulation outcome in a Parkinson's disease patient with Parkin gene mutation: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- The brain-first vs. body-first model of Parkinson's disease with comparison to alternative models.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Two-year clinical progression in focal and diffuse subtypes of Parkinson's disease.NPJ Parkinson's disease · 2023Article
- Cognitive Correlates of Visual and Minor Hallucinations in Parkinson's Disease.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2023Article
- Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson's Disease.Journal of Parkinson's disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 18 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe sought to evaluate demographic, clinical, and habits/occupational variables between phenotypic extremes in Parkinson's disease (PD).
methodsDatabases from nine movement disorders centers across seven countries were retrospectively searched for subjects meeting criteria for very slowly progressive, benign, PD (bPD) and rapidly progressive, malignant, PD (mPD). bPD was defined as Hoehn and Yahr (H&Y) stage ≤ 3, normal cognitive function, and Schwab and England (S&E) score ≥ 70 after ≥ 20 years of PD (≥ 10 years if older than 60 at PD onset); mPD as H&Y > 3, S&E score < 70, and cognitive impairment within 10 years from PD onset. We performed between-group analysis of demographic, habits/occupational, and clinical features at baseline and follow-up and unsupervised data-driven analysis of the clinical homogeneity of bPD and mPD.
resultsAt onset, bPD subjects (n = 210) were younger, had a single limb affected, lower severity and greater asymmetry of symptoms, and lower prevalence of depression than mPD (n = 155). bPD was associated with active smoking and physical activity, mPD with agricultural occupation. At follow-up, mPD showed higher prevalence of depression, hallucinations, dysautonomia, and REM behaviour disorder. Interestingly, the odds of mPD were significantly reduced by the presence of dyskinesia and wearing-off. Data-driven analysis confirmed the independent clustering of bPD and mPD, with age at onset emerging as a critical discriminant between the two groups (< 46-year-old vs. > 68-year-old).
conclusionsPhenotypic PD extremes showed distinct demographic, clinical, and habits/occupational factors. Motor complications may be conceived as markers of therapeutic success given their attenuating effects on the odds of mPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.